Evidence map›Paper›PMID 36385939›Full record

ArticleACS medicinal chemistry letters2022

Identification of Inhibitors of the

Indran Mathavan, Lawrence J Liu, Sean W Robinson, Nelly El-Sakkary, Adam Jo J Elatico, Darwin Gomez, Ricky Nellas, Raymond J Owens, William Zuercher, Iva Navratilova and 2 more

Open access · hybridAbstract read
In one paragraph

Article in ACS medicinal chemistry letters, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.9field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 3 countries.

Indran MathavanDepartment of Life Sciences, Imperial College London, Exhibition Road, London, South Kensington SW7 2AZ, United Kingdom.
Lawrence J LiuCenter for Discovery and Innovation in Parasitic Diseases, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, 9500 Gilman Drive, La Jolla, California 92093, United States.
Sean W RobinsonKinetic Discovery Ltd., an Exscientia group company, The Schrödinger Building, Oxford Science Park, Oxford OX4 4GE, United Kingdom.ORCID https://orcid.org/0000-0001-9312-7411
Nelly El-SakkaryCenter for Discovery and Innovation in Parasitic Diseases, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, 9500 Gilman Drive, La Jolla, California 92093, United States.
Adam Jo J ElaticoInstitute of Chemistry, College of Science, University of the Philippines Diliman, Quezon City, Philippines 1101.ORCID https://orcid.org/0000-0001-9765-1157
Darwin GomezInstitute of Chemistry, College of Science, University of the Philippines Diliman, Quezon City, Philippines 1101.
Ricky NellasInstitute of Chemistry, College of Science, University of the Philippines Diliman, Quezon City, Philippines 1101.
Raymond J OwensThe Rosalind Franklin Institute, Harwell Campus, Didcot, OX11 0QX, United Kingdom.ORCID https://orcid.org/0000-0002-3705-2993
William ZuercherStructural Genomics Consortium, Division of Chemical Biology and Medicinal Chemistry, UNC Eshelman School of Pharmacy, Chapel Hill, North Carolina 27599, United States.ORCID https://orcid.org/0000-0002-9836-0068
Iva NavratilovaKinetic Discovery Ltd., an Exscientia group company, The Schrödinger Building, Oxford Science Park, Oxford OX4 4GE, United Kingdom.ORCID https://orcid.org/0000-0003-2762-2056
Conor R CaffreyCenter for Discovery and Innovation in Parasitic Diseases, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, 9500 Gilman Drive, La Jolla, California 92093, United States.
Konstantinos BeisDepartment of Life Sciences, Imperial College London, Exhibition Road, London, South Kensington SW7 2AZ, United Kingdom.ORCID https://orcid.org/0000-0001-5727-4721
University of California San Diego · USUniversity of the Philippines Diliman · PHRutherford Appleton Laboratory · GBCentre for Human Genetics · GB

Funding

Development of thiophen-2-yl-phenylpyrimidines for treatment of schistosomiasisR21AI156554 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI BALLATORE, CARLO, CAFFREY, CONOR · 2021 to 2022
$435k
Medical Research Council MR/K018779/1Medical Research Council MR/N019113/1NIAID NIH HHS R21 AI156554Wellcome Trust
6 · The paper itself

Abstract

Schistosomiasis is a neglected tropical disease caused by parasitic flatworms. Current treatment relies on just one partially effective drug, praziquantel (PZQ).

Identifiers

PMID36385939
PMCPMC9661718
OpenAlexW4301606070

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.